Gutian Xiao, PhD


Dr. Xiao


Fax: 412-623-2525

1.19A Hillman Cancer Center

5117 Centre Avenue

Pittsburgh, PA 15213-1862


PhD in Molecular Genetics, Fudan University, Shanghai (P. R. China)

Research Summary

Our research interests focus primarily on the signaling transduction pathways involved in inflammation and cancer pathogenesis, for cancer preventive and therapeutic purposes.  In addition to our discovery of the noncanonical NF-κB signaling pathway and how this key signaling pathway is differentially de-regulated under various oncogenic conditions, we have provided the first evidence demonstrating the molecular mechanisms by which the canonical and noncanonical NF-κB signaling pathways deliberately collaborate for tumorigenesis.  We have also demonstrated, for the first time, a direct link between the NF-κB and autophagy signaling pathways under both physiological and oncogenic conditions.  Recently, we have demonstrated that the PDZ-LIM domain-containing protein PDLIM2 is an essential terminator of NF-κB and STAT activation, and that PDLIM2 functions as a haploinsufficient tumor suppressor.  We have also identified a novel gene that we have tentatively named NDO, an NF-κB-dependent oncogene.  Currently, we are utilizing both established and state-of-the-art technologies and resources, including innovative inducible conditional knockout or transgenic mice preclinical models, as well as human patient samples, to elucidate the molecular regulations and actions of the potentially drug-able PDLIM2 and NDO under physiological and oncogenic conditions.  We are also collaborating with physician scientists to translate our innovative findings into the clinical setting for the prognosis, prevention and treatment of human cancers, particularly breast, colon, lung, and hematologic malignancies. 

Research Lab Affiliation


Fu, J; Qu, Z; Yan, P; Ishikawa, C; Aqeilan, R. I; Rabson, A. B; and Xiao, G. (2011) The tumor suppressor gene WWOX links the canonical and noncanonical NF-κB pathways in HTLV-I Tax-mediated tumorigenesis. Blood. 117: 1652-1661. |  View Abstract

Fu, J; Yan, P; Li, S; Qu, Z; and Xiao, G. (2010) Molecular determinants of PDLIM2 in suppressing HTLV-I Tax-mediated tumorigenesis. Onocogene. 29: 6499-6507. |  View Abstract

Qu, Z; Fu, J; Yan, P; Hu, J; Cheng, S. Y; and Xiao, G. (2010) Epigenetic repression of PDZ-LIM domain-containing protein 2: implications for the biology and treatment of breast cancer. J Biol Chem. 285: 11786-11792. |  View Abstract

Qu, Z; Yan, P; Fu, J; Jiang, J; Grusby, M. J; Smithgall, T. E; and Xiao, G. (2010) DNA methylation-dependent repression of PDZ-LIM domain-containing protein 2 in colon cancer and its role as a potential therapeutic target. Cancer Res. 70: 1766-1772. |  View Abstract

Yan, P; Fu, J; Qu, Z; Li, S; Tanaka, T; Grusby, M. J; and Xiao, G. (2009) PDLIM2 suppresses HTLV-I Tax-mediated tumorigenesis by Targeting Tax into the nuclear matrix for proteasomal degradation. Blood. 113: 4370-4380. |  View Abstract

Qing, G; Yan, P; Qu, Z; Liu, H; and Xiao, G. (2007) Hsp90 regulates processing of NF-kappa B2 p100 involving protection of NF-kappa B-inducing kinase (NIK) from autophagy-mediated degradation. Cell Res. 17: 520-530. |  View Abstract

Qing, G; Qu, Z; and Xiao, G. (2007) Endoproteolytic processing of C-terminally truncated NF-kappaB2 precursors at kappaB-containing promoters. Proc Natl Acad Sci USA. 104: 5324-5329. |  View Abstract